Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Interferon for acute hepatitis C.

T Poynard¹, C Regimbeau, R P Myers

¹Service d'Hepato-Gastroenterologie, Groupe Hospitalier Pitie-Salpetriere, Paris, France, 47-83 boulevard de l'Hopital, Paris Cedex 13, France, 75651. tpoynard@teaser.fr

The Cochrane Database of Systematic Reviews

|March 1, 2002

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Management of severe acute alcoholic hepatitis in France: results of a national survey: R1.

Clinics and research in hepatology and gastroenterology·2026

Same author

Reply.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026

Same author

Good outcome of liver transplantation in patients with pre-existing renal cell carcinoma.

Clinics and research in hepatology and gastroenterology·2023

Same author

Correction to: The MELD Score Is Superior to the Maddrey Discriminant Function Score to Predict Short-Term Mortality in Alcohol-Associated Hepatitis: A Global Study.

The American journal of gastroenterology·2022

Same author

Dunnigan lipodystrophy syndrome: French National Diagnosis and Care Protocol (PNDS; Protocole National de Diagnostic et de Soins).

Orphanet journal of rare diseases·2022

Same author

The MELD Score Is Superior to the Maddrey Discriminant Function Score to Predict Short-Term Mortality in Alcohol-Associated Hepatitis: A Global Study.

The American journal of gastroenterology·2021

Same journal

Interventions to prevent or cease electronic cigarette use in children and adolescents.

The Cochrane database of systematic reviews·2026

Same journal

Drugs to improve anaemia, quality of life, and physical function in people with myelodysplastic syndromes (MDS).

The Cochrane database of systematic reviews·2026

Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026

Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026

Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026

Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026

See all related articles

Interferon alfa effectively treats acute hepatitis C virus (HCV) infection, improving viral clearance rates. This treatment is crucial for preventing chronic hepatitis C progression.

Area of Science:

Hepatology
Virology
Clinical Medicine

Background:

Acute hepatitis C virus (HCV) infection frequently progresses to chronic disease.
Interferon therapy has been investigated to prevent HCV chronicity.

Purpose of the Study:

To assess the efficacy of interferon in treating acute HCV infection.
To evaluate interferon's role in preventing chronic hepatitis C.

Main Methods:

Systematic review of randomized clinical trials comparing interferon with placebo or no treatment.
Searched MEDLINE, Cochrane Controlled Trials Register, and conference abstracts.
Analyzed biochemical and virologic endpoints, including sustained viral clearance.

Main Results:

Related Experiment Videos

Interferon alfa-2b significantly increased virologic clearance rates (ETR and SR) in transfusion-acquired acute HCV.
Virologic end-of-treatment clearance (ETR) was 42% with interferon alfa-2b vs. 4% in controls.
Sustained virologic clearance (SR) at follow-up was 32% with interferon alfa-2b vs. 4% in controls.
Efficacy of interferon beta could not be assessed due to trial heterogeneity.

Conclusions:

Interferon alfa demonstrates efficacy in achieving biochemical improvements and sustained virologic clearance for acute HCV.
The impact of interferon alfa on long-term clinical outcomes remains undetermined due to data limitations.